| pubmed-article:18975570 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18975570 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18975570 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:18975570 | lifeskim:mentions | umls-concept:C0007138 | lld:lifeskim |
| pubmed-article:18975570 | lifeskim:mentions | umls-concept:C0079083 | lld:lifeskim |
| pubmed-article:18975570 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:18975570 | lifeskim:mentions | umls-concept:C0009429 | lld:lifeskim |
| pubmed-article:18975570 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
| pubmed-article:18975570 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:18975570 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:18975570 | lifeskim:mentions | umls-concept:C0556895 | lld:lifeskim |
| pubmed-article:18975570 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:18975570 | pubmed:dateCreated | 2008-11-3 | lld:pubmed |
| pubmed-article:18975570 | pubmed:abstractText | From 2001 to 2006, 11 patients with MVAC-treated metastatic urothelial carcinoma received as a second-line therapy GDC therapy consisting of gemcitabine (1,000 mg/m2) on day land 8, docetaxel (80 mg/m2) on day 1 and carboplatin (AUC 5) on day 1 in each 21-day cycle. The 11 patients received a total of 42 cycles. The median progression-free survival and the median overall survival were 3 months (range 0-51) and 10 months (range 2-51), respectively. The median overall survival from diagnosis of the metastasis was 13.0 months (range 7-55). Complete response and partial response rates were 1/11 (9%) and 5/11 (45%), respectively. One- and two-year survival rates were 36 and 9%, respectively. Grade 3 or 4 hematologic toxicity included neutropenia (69.0%), thrombocytopenia (47.6%) and anemia (45.2%). Non-hematologic toxicity of grade 3 or 4 consisted mainly of diarrhea (23.8%) and anorexia (21.4%). GDC regimen as a second-line chemotherapy was effective in 54% of patients with MVAC-treated metastatic urothelial carcinoma, although the high incidence of hematologic toxicities and short period of progression-free survival remain to be major problems. | lld:pubmed |
| pubmed-article:18975570 | pubmed:language | jpn | lld:pubmed |
| pubmed-article:18975570 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18975570 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18975570 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18975570 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18975570 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18975570 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18975570 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18975570 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18975570 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18975570 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18975570 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18975570 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18975570 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:18975570 | pubmed:issn | 0018-1994 | lld:pubmed |
| pubmed-article:18975570 | pubmed:author | pubmed-author:SaitoMitsuruM | lld:pubmed |
| pubmed-article:18975570 | pubmed:author | pubmed-author:SatohShigeruS | lld:pubmed |
| pubmed-article:18975570 | pubmed:author | pubmed-author:TsuchiyaNorih... | lld:pubmed |
| pubmed-article:18975570 | pubmed:author | pubmed-author:HabuchiTomono... | lld:pubmed |
| pubmed-article:18975570 | pubmed:author | pubmed-author:YuasaTakeshiT | lld:pubmed |
| pubmed-article:18975570 | pubmed:author | pubmed-author:InoueTakamits... | lld:pubmed |
| pubmed-article:18975570 | pubmed:author | pubmed-author:HorikawaYohei... | lld:pubmed |
| pubmed-article:18975570 | pubmed:author | pubmed-author:NaritaShintar... | lld:pubmed |
| pubmed-article:18975570 | pubmed:author | pubmed-author:KumazawaTerua... | lld:pubmed |
| pubmed-article:18975570 | pubmed:author | pubmed-author:ObaraTakashiT | lld:pubmed |
| pubmed-article:18975570 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18975570 | pubmed:volume | 54 | lld:pubmed |
| pubmed-article:18975570 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18975570 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18975570 | pubmed:pagination | 581-5 | lld:pubmed |
| pubmed-article:18975570 | pubmed:meshHeading | pubmed-meshheading:18975570... | lld:pubmed |
| pubmed-article:18975570 | pubmed:meshHeading | pubmed-meshheading:18975570... | lld:pubmed |
| pubmed-article:18975570 | pubmed:meshHeading | pubmed-meshheading:18975570... | lld:pubmed |
| pubmed-article:18975570 | pubmed:meshHeading | pubmed-meshheading:18975570... | lld:pubmed |
| pubmed-article:18975570 | pubmed:meshHeading | pubmed-meshheading:18975570... | lld:pubmed |
| pubmed-article:18975570 | pubmed:meshHeading | pubmed-meshheading:18975570... | lld:pubmed |
| pubmed-article:18975570 | pubmed:meshHeading | pubmed-meshheading:18975570... | lld:pubmed |
| pubmed-article:18975570 | pubmed:meshHeading | pubmed-meshheading:18975570... | lld:pubmed |
| pubmed-article:18975570 | pubmed:meshHeading | pubmed-meshheading:18975570... | lld:pubmed |
| pubmed-article:18975570 | pubmed:meshHeading | pubmed-meshheading:18975570... | lld:pubmed |
| pubmed-article:18975570 | pubmed:meshHeading | pubmed-meshheading:18975570... | lld:pubmed |
| pubmed-article:18975570 | pubmed:meshHeading | pubmed-meshheading:18975570... | lld:pubmed |
| pubmed-article:18975570 | pubmed:meshHeading | pubmed-meshheading:18975570... | lld:pubmed |
| pubmed-article:18975570 | pubmed:meshHeading | pubmed-meshheading:18975570... | lld:pubmed |
| pubmed-article:18975570 | pubmed:meshHeading | pubmed-meshheading:18975570... | lld:pubmed |
| pubmed-article:18975570 | pubmed:meshHeading | pubmed-meshheading:18975570... | lld:pubmed |
| pubmed-article:18975570 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18975570 | pubmed:articleTitle | [Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma]. | lld:pubmed |
| pubmed-article:18975570 | pubmed:affiliation | Department of Urology, Akita University School of Medicine, Akita, Japan. | lld:pubmed |
| pubmed-article:18975570 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18975570 | pubmed:publicationType | English Abstract | lld:pubmed |
